Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Jeffrey S. Weber, Georgina V. Long, Dirk Schadendorf et al.|Journal of Clinical Oncology|2022Cited by 166
Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markersVishal Navani, André van der Westhuizen, Moira C. Graves et al.|Pharmacology Research & Perspectives|2021Cited by 10
Business as unusual: medical oncology services adapt and deliver during <scp>COVID</scp>‐19Avraham Travers, James Lynam, Louise Plowman et al.|Internal Medicine Journal|2021Cited by 9
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)Fiona Day, Jarad Martin, Swetha Sridharan et al.|BMC Cancer|2022Cited by 6
Melanoma: An immunotherapy journey from bench to bedsideVishal Navani, Nikola A. Bowden, Moira C. Graves et al.|Cancer treatment and research|2022Cited by 2